Evidence map›Paper›PMID 32817283›Full record

ArticleHaematologica2021

The multifaceted role of protein kinase CK2 in high-risk acute lymphoblastic leukemia.

Yun Zhou, Haiwei Lian, Ning Shen, Sovannarith Korm, Andrew Kwok Ping Lam, Olivia Layton, Leah N Huiting, Dun Li, Kelly Miao, Aozhuo Zeng and 5 more

Abstract readLetter
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yun ZhouDepartment of Gynecology, Wuhan University Renmin Hospital, Wuhan, Hubei, P. R. China.
Haiwei LianDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Ning ShenDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Sovannarith KormDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Andrew Kwok Ping LamDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Olivia LaytonDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Leah N HuitingDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Dun LiDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Kelly MiaoDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Aozhuo ZengDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Esther Landesman-BollagDepartment of Medicine, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA, USA.
David C SeldinDepartment of Medicine, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA, USA.
Hui FuDepartment of Anatomy and Embryology, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei, P. R. China.
Li HongDepartment of Gynecology, Wuhan University Renmin Hospital, Wuhan, Hubei, P. R. China.
Hui FengDepartment of Pharmacology and Experimental Therapeutics, Department of Medicine, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA, USA.

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
RESEARCH TRAINING IN BLOOD DISEASES AND RESOURCEST32HL007501 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LERNER, ADAM, STEINBERG, MARTIN H. · 1985 to 2018
$5.4M
TRAINING IN BIOMOLECULAR PHARMACOLOGYT32GM008541 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARB, DAVID H · 1997 to 2022
$5.2M
The Role of DLST in LeukemogenesisR01CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2018 to 2022
$2.0M
"Oncorequisite" Genes in MYC-mediated TransformationR00CA134743 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2012 to 2014
$712k
The Role of DLST in LeukemogenesisR56CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2017 to 2017
$376k
"Oncorequisite" Genes in MYC-mediated TransformationK99CA134743 · NCI · DANA-FARBER CANCER INST · PI FENG, HUI · 2009 to 2010
$282k
NCATS NIH HHS UL1 TR001430NCI NIH HHS K99 CA134743NCI NIH HHS R00 CA134743NCI NIH HHS R01 CA215059NCI NIH HHS R56 CA215059NHLBI NIH HHS T32 HL007501NIGMS NIH HHS T32 GM008541
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Casein Kinase IIPrecursor Cell Lymphoblastic Leukemia-LymphomaGene Expression Regulation, LeukemicHumansIkaros Transcription FactorCasein Kinase IIIkaros Transcription Factor

Identifiers

PMID32817283
PMCPMC8094085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.